Tocilizumab and sarilumab are classified as humanized monoclonal antibodies against the interleukin-6 receptor and are used in rheumatology.

CADTH has conducted a Technology Review on tocilizumab and sarilumab for their potential use in managing COVID-19.

Link to Report

Tocilizumab and Sarilumab: Evidence Review and Appraisal (updated February 25, 2021)

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.